Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma

Inclusion Criteria: * Histological diagnosis of thoracic Esophageal squamous cell carcinoma * ECOG performance status 0-1 * Age 18-75 years * Resectable disease, cT2-4aNanyM0 or cT1-3N+M0 * Life expectancy more than 6 months * Use of an effective contraceptive for adults to prevent pregnancy Exclusion Criteria: * Not suitable for surgery * Prior chemotherapy, radiotherapy and immune-oncology therapies for ESCC * Prior esophageal, gastric, or gastro-esophageal junction surgery * Esophageal ulcer, esophageal perforation，chest pain（≥middle level） * Pregnant or lactating women